REAL-WORLD USAGE OF BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS IN GERMANY

被引：0
|
作者：
Anjohrin, S. [1 ]
Song, J. [1 ,2 ]
Abe, C. [2 ,3 ]
Banefelt, J. [3 ]
Dun, Rieem A. [3 ]
Picker, N. [4 ]
Kromer, D. [5 ]
Fuchs, A. [6 ]
Hahn, P. [7 ]
Welby, S. [8 ]
机构：
[1] UCB Pharma, Brussels, Belgium
[2] Karolinska Inst, Stockholm, Sweden
[3] Quantify Res, Stockholm, Sweden
[4] Cytel, Wismar, Germany
[5] Cytel, Berlin, Germany
[6] AOK PLUS, Dresden, Saxony, Germany
[7] Inst Pharmakookon & Arzneimittellogist IPAM, Wismar, Germany
[8] UCB Pharma, Anderlecht, Belgium
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
HSD34
引用
收藏
页码：S300 / S300
页数：1
相关论文
共 50 条
  • [1] REAL-WORLD USAGE OF BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS IN PATIENTS WITH PSORIATIC ARTHRITIS IN GERMANY
    Song, J.
    Anjohrin, S.
    Abe, C.
    Banefelt, J.
    Rieem, Dun A.
    Picker, N.
    Kromer, D.
    Fuchs, A.
    Hahn, P.
    Welby, S.
    VALUE IN HEALTH, 2023, 26 (12) : S305 - S305
  • [2] Knowledge mapping of biological disease-modifying anti-rheumatic drugs for axial spondyloarthritis: a bibliometric study
    Qian He
    Jia-qi Chen
    Xin-bo Yu
    Jia-he Liao
    Zi-wei Huang
    Jian-ying Yang
    Tzu-Hua Wu
    Wei-jiang Song
    Jing Luo
    Qing-wen Tao
    Clinical Rheumatology, 2023, 42 : 1999 - 2011
  • [3] Knowledge mapping of biological disease-modifying anti-rheumatic drugs for axial spondyloarthritis: a bibliometric study
    He, Qian
    Chen, Jia-qi
    Yu, Xin-bo
    Liao, Jia-he
    Huang, Zi-wei
    Yang, Jian-ying
    Wu, Tzu-Hua
    Song, Wei-jiang
    Luo, Jing
    Tao, Qing-wen
    CLINICAL RHEUMATOLOGY, 2023, 42 (08) : 1999 - 2011
  • [4] Real-World Treatment Effectiveness of Disease-Modifying Anti-Rheumatic Drugs by Serostatus Among Patients with Rheumatoid Arthritis
    Jin, Yinzhu
    Liu, Jun
    Desai, Rishi
    Kim, Seoyoung
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 1428 - 1429
  • [5] Effect of biologic disease-modifying anti-rheumatic drugs targeting remission in axial spondyloarthritis: systematic review and meta-analysis
    Cruz-Machado, Ana Rita
    Rodrigues-Manica, Santiago
    Silva, Joana Leite
    Alho, Irina
    Coelho, Constanca
    Duarte, Joana
    Florencio, Claudia
    Pimentel-Santo, Fernando M.
    Tavares-Costa, Jose
    Vieira-Sousa, Elsa
    RHEUMATOLOGY, 2020, 59 (11) : 3158 - 3171
  • [6] Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis
    Choy, Ernest
    Aletaha, Daniel
    Behrens, Frank
    Finckh, Axel
    Gomez-Reino, Juan
    Gottenberg, Jacques-Eric
    Schuch, Florian
    Rubbert-Roth, Andrea
    RHEUMATOLOGY, 2017, 56 (05) : 689 - 697
  • [7] Cardiovascular Effects of Biologic Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
    Drakopoulou, Maria
    Soulaidopoulos, Stergios
    Oikonomou, George
    Tousoulis, Dimitrios
    Toutouzas, Konstantinos
    CURRENT VASCULAR PHARMACOLOGY, 2020, 18 (05) : 488 - 506
  • [8] Utilization of biologic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis and cancer
    Xerxes Pundole
    Natalia V. Zamora
    Harish Siddhanamatha
    Heather Lin
    Jean Tayar
    Leung Cheuk Hong
    Liang Li
    Maria E. Suarez-Almazor
    Clinical Rheumatology, 2020, 39 : 787 - 794
  • [9] Utilization of biologic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis and cancer
    Pundole, Xerxes
    Zamora, Natalia V.
    Siddhanamatha, Harish
    Lin, Heather
    Tayar, Jean
    Hong, Leung Cheuk
    Li, Liang
    Suarez-Almazor, Maria E.
    CLINICAL RHEUMATOLOGY, 2020, 39 (03) : 787 - 794
  • [10] Pharmacogenetics of disease-modifying anti-rheumatic drugs
    Tanaka, E
    Taniguchi, A
    Urano, W
    Yamanaka, H
    Kamatani, N
    BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2004, 18 (02): : 233 - 247
12345